CTNNA1 hypermethylation could be an independent prognostic factor for poor RFS in AML 46; therefore, genome sequencing or immunohistochemistry may be used to investigate the role of CTNNA1 methylomics in ovarian cancer or the specific impact of prognoses related to chemotherapy or immunosuppressive therapy. Here, CTNNA1 is linked to ovarian cancer.